Antibody is an immune protein that binds to an antigen to inhibit its activity or stimulate neutralization or activation. Although it is a protein generated in the immune system originally. Antibody is available to be mass-produced, purified, and analyzed into monoclonal antibody, regarding specific antibodies with selectivity and specificity against specific antigens.
VM507 is an antibody that can detect and activate c-MET, receptor of hepatocyte growth factor (HGF). As a fully human antibody, it has the potential to be safe immunologically, transmissible via blood vessel injection or local injection to other various tissues and organs, and the longer half-life may contribute to improved efficacy.
The c-Met level is especially high in patients with chronic/acute renal disease. VM507 showed therapeutic efficacies such as inhibition of renal fibrosis and improvement of functional index by binding with c-MET receptor in the renal tissue when injected intravenously in the mouse model of renal disease.
VM507
VM507, Helixmith’s leading antibody treatment,
is an antibody that can detect and
activate c-MET (HGF receptor).
이메일무단수집거부
이메일주소 무단수집을 거부합니다.
본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나 그 밖의 기술적 장치를 이용하여 무단으로 수집되는 것을 거부하며, 이를 위반시 정보통신망법에 의해 형사 처벌됨을 유념하시기 바랍니다.
Overview
VM507
Improvement of renal disease
Inhibition of renal fibrosis
01 Administration route and mechanism
·Capable of selective transmission
intravenously injection or
local injection to various lesions
· Retaining efficacy for long term
due to longer half-life
02 Substance characteristics
·Antibody to detect and activate c-Met,
a receptor of HGF
·Immune toxicity-free in human application
as a fully human antibody
Status of clinical trials
Scroll
| Indication | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Antibody | VM507 | Chronic Kidney Disease |
|
|||